Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature
Acta Haematologica · 24.02.2024 · 147 (5) · 604-611
DOI: 10.1159/000537791 ↗Kurz gefasst
Fallbericht in der Zeitschrift Acta Haematologica, online erschienen am 24.02.2024. Verfasst von Thomas Parigger und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Ca…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Agammaglobulinaemia Tyrosine Kinase, TOR Serine-Threonine Kinases, Adenine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Targeting the B-cell receptor pathway via ibrutinib, a specific inhibitor of Bruton’s tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred first line option independent of risk factors. However, acquired resistance to ibrutinib poses a major clinical problem and requires the development of novel treatment combinations to increase efficacy and counteract resistance development and clinical relapse rates. Case Presentation: In this study, we performed exome and transcriptome analyses of an ibrutinib resistant CLL patient in order to investigate genes and expression patterns associated with ibrutinib resistance. Here, we provide evidence that ibrutinib resistance can be attributed to aberrant mammalian target of rapamycin (MTOR) signaling.
Conclusion
Thus, our study proposes that combined use of MTOR inhibitors with ibrutinib could be a possible option to overcome therapy resistance in ibrutinib treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular C…
- Department of Biosciences, Paris-Lodron-University Salzburg, Salzburg, Austria.
- Institute of Pathology, Paracelsus Medical University, Salzburg, Austria.
- Laboratory for Molecular Cytology (MZL), Salzburg, Austria.
Zitieren
APA
Parigger, T., Drothler, S., Scherhäufl, C., Gassner, F. J., Schubert, M., Steiner, M., Höpner, J. P., Hödlmoser, A., Schultheis, L., Bakar, A. A., Neureiter, D., Pleyer, L., Egle, A., Greil, R., Geisberger, R., & Zaborsky, N. (2024). Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature. Acta Haematologica, 147(5), 604-611. https://doi.org/10.1159/000537791
Vancouver
Parigger T, Drothler S, Scherhäufl C, Gassner FJ, Schubert M, Steiner M, et al. Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature. Acta Haematologica. 2024;147(5):604-611. doi:10.1159/000537791
BibTeX
@article{Parigger2024,
author = {Parigger, Thomas and Drothler, Stephan and Scherhäufl, Christian and Gassner, Franz Josef and Schubert, Maria and Steiner, Markus and Höpner, Jan Philip and Hödlmoser, Alexandra and Schultheis, Lena and Bakar, Aryunni Abu and Neureiter, Daniel and Pleyer, Lisa and Egle, Alexander and Greil, Richard and Geisberger, Roland and Zaborsky, Nadja},
title = {Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature},
journal = {Acta Haematologica},
year = {2024},
volume = {147},
number = {5},
pages = {604--611},
doi = {10.1159/000537791}
}
EUVIMED